Indication

CCND2

1 clinical trial

2 products

Clinical trial

A Phase II Study of Ibrutinib Plus Rituximab in Patients With Relapsed/Refractory Mantle Cell Lymphoma or Elderly Patients With Newly Diagnosed MCL

Status: Active (not recruiting), Estimated PCD: 2024-07-31

Product

Product